Radon and cancer

Radon is a naturally occurring radioactive gas that accumulates in buildings, particularly in basements and lower levels where soil gas entry is highest. As a decay product of uranium in soil and rocks, radon concentrations vary dramatically by geography, with some regions having average indoor radon levels five to ten times the United States Environmental Protection Agency (EPA) action level. The proposed mechanism for cancer causation involves alpha particle radiation from radon decay products directly damaging lung tissue DNA, inducing mutations in genes critical for cancer suppression. Lung cancer is the primary cancer of concern, as radon and its decay products are inhaled during breathing and deposit in the respiratory tract.

Radon decays into short-lived progeny including polonium-218 and polonium-214 that emit high-energy alpha particles. When radon and its progeny are inhaled, alpha particles deposit energy along short trajectories through lung epithelial cells, creating extremely dense tracks of DNA damage including double-strand breaks. Alpha particles are highly ionizing, approximately 100-1000 times more damaging per unit energy than sparsely ionizing radiation due to their high linear energy transfer. These breaks, if incorrectly repaired through non-homologous end joining rather than homologous recombination, can lead to mutations in genes critical for cancer suppression, particularly TP53 and KRAS. Chronic alpha particle exposure from radon creates a state of persistent inflammation and genomic instability in the epithelium, facilitating the multi-hit accumulation of mutations required for malignant transformation. Studies in uranium miners, who experienced high radon exposure in underground mines for occupational reasons, established the lung cancer risk clearly through occupational epidemiology before the residential exposure risk was fully characterized.

Epidemiological studies conducted in multiple countries, including large studies in the United States, Canada, and Europe, consistently demonstrate increased lung cancer risk associated with residential radon exposure. The European pooling project on residential radon and lung cancer risk, combining data from multiple countries, found that radon exposure increased lung cancer risk in a dose-dependent manner: approximately 10 percent increased risk per 100 becquerels per cubic meter (Bq/m3) increase in radon concentration. Case-control studies in radon-prone regions such as the United Kingdom and Scandinavia show similar effect sizes. The relationship is evident even at radon levels below current EPA action levels of 4 Bq/m3. Smoking appears to interact with radon exposure synergistically: smokers exposed to elevated radon face much higher risk than would be predicted from either exposure alone, suggesting multiplicative interaction. Studies of uranium miners exposed to very high radon levels (often exceeding 10,000 Bq/m3) showed 15-30 fold increased lung cancer risk. Mechanistic studies confirm radon-induced DNA damage and genomic instability in in vitro cell models and animal models, validating the proposed pathways.

Individuals living in radon-prone geographic regions with granitic geology or certain soil types face the highest baseline radon exposure risk. Residents of older homes with poor ventilation, cracks in foundations, and many entry points for soil gas accumulate higher indoor radon levels than residents of newer, tightly sealed homes. Smokers living in high-radon areas face substantially elevated risk due to the synergistic interaction between smoking and radon exposure. Nonsmokers in very high-radon homes also show elevated risk, though absolute cancer rates remain lower than in smokers due to lower baseline lung cancer incidence. Individuals with occupational radiation exposure from other sources including medical imaging or nuclear industry work may face additive risk when combined with residential radon. Long-term residents of high-radon areas accumulate greater cumulative exposure and face higher cancer incidence than recent arrivals.

The evidence linking residential radon to lung cancer risk is strong, based on multiple epidemiological studies in diverse populations showing consistent dose-response relationships across different geographic contexts. Mechanistic understanding of radon as an alpha-particle-emitting radiation source is straightforward and well-established through radiation physics. The evidence from uranium miners provides clear evidence of causation at higher exposure levels. The main area of uncertainty is the precise risk at lower residential exposures and whether reducing radon in homes below current action levels provides measurable lung cancer reduction at the individual level. Some studies have attempted radon remediation randomized trials but have not yet definitively demonstrated lung cancer reduction through a randomized trial, though this may reflect the long latency period for cancer development and statistical power limitations. The evidence is sufficient that major health organizations including the EPA and American Lung Association recommend radon testing and remediation above action levels.

Radon testing is recommended for all homes, particularly in geographic regions with known radon potential such as areas with granitic bedrock. For homes with elevated radon above EPA action levels, radon remediation through ventilation improvements and soil depressurization is a reasonable investment for cancer risk reduction. The benefit is particularly clear for smokers living in high-radon areas, who can reduce lung cancer risk substantially through both smoking cessation and radon remediation. For nonsmokers, radon reduction provides incremental cancer risk reduction. Radon mitigation is cost-effective compared to many other health interventions and represents an accessible approach to environmental risk reduction.